Is Teladoc a Better Buy than Amwell?

Telehealth giant Teladoc (NYSE: TDOC) has seen its shares dip considerably in recent months, but the business is stronger than ever. In this segment of Backstage Pass, recorded on Jan. 12, Fool contributor Rachel Warren responds to a member's question about the company and one of its most well-known competitors, Amwell (NYSE: AMWL).

Source Fool.com